secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K/A
Filed at:   2026-04-24T23:59:59+00:00
Accession:  0001493152-26-018954
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Matthew McMurdo Resigns
--------------------------------------------------------------------------------

- Tim Ruan, 40, CFO of Ocumension Therapeutics and former Executive Director at Goldman Sachs, appointed as Class II director.
- Dr. Johnny Fox Arrowsmith (Yi Zhang), 48, partner at JunHe and registered patent attorney, appointed as Class II director.
- Matthew McMurdo resigned as director on April 22, 2026; resignation not due to any disagreement with company.
- Each new director receives annual cash retainer of $30,000, payable quarterly, plus expense reimbursement and indemnification.
- Ruan appointed to Audit Committee; Arrowsmith appointed to Nominating Committee. New directors effective April 22, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226018954/0001493152-26-018954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226018954/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-018954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer